 "Kiran Mazumdar Shaw, Biocon CMD")
Biopharmaceutical major Biocon has announced that the Board of its subsidiary Biocon Biologics has approved a capital injection of $150 million from global banking and investment firm Goldman Sachs.
According to the terms of the proposed agreement, Goldman Sachs will be issued Optionally Convertible Debentures at a post money equity valuation of $3.94 billion. The transaction is subject to customary approvals and conditions.
“We are extremely pleased to welcome a capital injection by Goldman Sachs at this inflection point of Biocon Biologics’ journey in its quest for global leadership in providing affordable access through Biosimilar drugs. This transaction is a
